Cipla Shares Decline 3.5% Amid High Trading Volume Despite Strong Financial Performance
Cipla shares declined 3.5% to ₹1,322.40 amid high trading volume, despite strong financial performance showing quarterly sales growth to ₹7,589 crores in September 2025. The pharmaceutical company demonstrated consistent annual growth with sales increasing from ₹19,159 crores in March 2021 to ₹27,547 crores in March 2025, while net profit more than doubled to ₹5,291 crores. Key financial metrics indicate healthy operations with improved profit margins, strong balance sheet position, and a debt-to-equity ratio of 0.00.

*this image is generated using AI for illustrative purposes only.
Cipla shares experienced a decline of 3.5% to ₹1,322.40 during Friday's trading session, despite the pharmaceutical company's strong financial performance across multiple quarters. The stock, which is a constituent of the Nifty 50 index, witnessed high trading volume during the session.
Strong Quarterly Performance
The company's consolidated quarterly financial data reveals robust performance, with sales showing consistent growth trajectory. The September 2025 quarter demonstrated particularly strong results compared to the previous year.
| Quarter | Sep 2025 | Sep 2024 | Growth |
|---|---|---|---|
| Sales | ₹7,589 cr | ₹7,051 cr | +7.63% |
| Net Profit | ₹1,353 cr | ₹1,306 cr | +3.60% |
| EBIT | ₹1,866 cr | ₹1,804 cr | +3.44% |
The quarterly progression also shows sequential improvement, with sales increasing from ₹6,957 crores in June 2025 to ₹7,589 crores in September 2025.
Annual Financial Growth Trajectory
Cipla's consolidated annual financial performance demonstrates sustained growth over the past five years. The company has consistently expanded its revenue base while improving profitability metrics.
| Year | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Sales | ₹27,547 cr | ₹25,774 cr | ₹22,753 cr | ₹21,763 cr | ₹19,159 cr |
| Net Profit | ₹5,291 cr | ₹4,155 cr | ₹2,835 cr | ₹2,559 cr | ₹2,401 cr |
| EBIT | ₹6,882 cr | ₹5,791 cr | ₹4,147 cr | ₹3,599 cr | ₹3,450 cr |
The five-year growth shows sales increasing by 43.77% from March 2021 to March 2025, while net profit more than doubled during the same period, representing a 120.45% increase.
Balance Sheet Strength
The company's consolidated balance sheet reflects strong financial health with substantial asset growth. Total assets increased from ₹25,151 crores in March 2021 to ₹37,387 crores in March 2025. Current assets showed particularly strong growth, rising from ₹13,209 crores to ₹23,288 crores over the five-year period.
Key Financial Ratios and Metrics
Cipla's financial ratios indicate a well-managed company with improving operational efficiency. The debt-to-equity ratio has decreased significantly to 0.00 as of March 2025, compared to 0.08 in March 2021.
| Metric | Mar 2025 | Mar 2024 | Mar 2021 |
|---|---|---|---|
| Basic EPS | ₹65.29 | ₹51.05 | ₹29.82 |
| Net Profit Margin | 19.20% | 16.12% | 12.53% |
| Return on Equity | 16.90% | 15.43% | 13.12% |
| Current Ratio | 4.25 | 3.71 | 2.88 |
| P/E Ratio | 22.09 | 29.32 | 27.33 |
Cash Flow Performance
The company's cash flow from operating activities has shown consistent improvement, reaching ₹5,004 crores in March 2025, up from ₹3,755 crores in March 2021. This represents a 33.26% increase in operational cash generation over the five-year period.
Corporate Actions History
Cipla has a history of rewarding shareholders through various corporate actions. The company announced its most recent bonus issue on February 11, 2006, with a bonus ratio of 3:2. Additionally, the company conducted a stock split on March 23, 2004, reducing the face value from ₹10 to ₹2, with the ex-split date on May 11, 2004.
Historical Stock Returns for Cipla
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.14% | -6.03% | -12.49% | -10.88% | -9.51% | +56.93% |


































